February 21, 2024Open Access

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Key Points

Key points are not available for this paper at this time.

Abstract

RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primary endpoint of noninferiority in overall survival (OS). This analysis compared health-related quality-of-life (HRQOL) outcomes between the arms.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Richard S. Finn

Masatoshi Kudo

Gisoo Barnes

Journals

Liver Cancer

Actions

Institutions

Harvard University

University of California, Los Angeles

University College London

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study